Skip to main content
SHINIL PHARMACEUTICAL CO., LTD. logo

SHINIL PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 012790 ISIN · KR7012790002 KO Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2021-03-29 Declaration of Voting R…
Country KR South Korea
Listing KO 012790

About SHINIL PHARMACEUTICAL CO., LTD.

https://shinilpharma.com/

SHINIL PHARMACEUTICAL CO., LTD. is a drug manufacturing company that develops, produces, and sells a diverse range of pharmaceutical products. The company's portfolio encompasses various therapeutic areas, including vitamins, mineral supplements, anti-inflammatory enzymes, antihistamines, appetite stimulants, and treatments for liver disease. Its product offerings also include topical medications such as gels and medicated plasters. The company serves both domestic and international markets.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Shareholders' Meeting (AGM) for Shinil Pharmaceutical. It details the outcomes of agenda items such as financial statement approval, dividend declarations, and the election of directors. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides the official results of shareholder votes.
2021-03-29 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details changes to the board of directors, specifically regarding outside directors, which falls under the category of Board/Management Information.
2021-03-29 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal announcement from Shinil Pharmaceutical regarding the submission of an audit report. It provides key financial data (assets, liabilities, revenue, net income) and the auditor's opinion (unqualified/proper). While it contains financial data, it is a short regulatory disclosure announcing the completion and submission of the audit report to the exchange, rather than the full annual report or a standalone audit document. Therefore, it fits the criteria for a Report Publication Announcement (RPA). FY 2020
2021-03-19 Korean
사업보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Shinil Pharmaceutical Co., Ltd. for the fiscal year ending December 31, 2020. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. While it contains financial data, it is specifically the formal audit report required by law, which is distinct from a standard 10-K or interim report. Given the specific category 'Audit Report / Information' (AR) is available and the document is a full audit report, it fits this category perfectly. FY 2020
2021-03-19 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) which includes the agenda, financial statements, and proposed resolutions for the 44th Annual General Meeting. It contains detailed information regarding the meeting date, location, agenda items (financial statement approval, director appointments, etc.), and proxy information. This type of document is standard for providing shareholders with the necessary information to vote at an AGM, fitting the definition of a Proxy Solicitation & Information Statement.
2021-03-15 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Shinil Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, dividend declaration, and director appointments) for the upcoming Annual General Meeting. This document serves as the official solicitation and notification to shareholders regarding the meeting's proceedings, which aligns with the definition of a Proxy Solicitation & Information Statement.
2021-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.